Brady Matthew T, Patts Gregory J, Rosen Amy, Kasotakis George, Siracuse Jeffrey J, Sachs Teviah, Kuhnen Angela, Kunitake Hiroko
1 Department of Surgery, Boston University School of Medicine, Boston, Massachusetts 2 Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 3 Optum Visiting Fellow, Boston University School of Medicine, Boston, Massachusetts.
Dis Colon Rectum. 2017 Jan;60(1):61-67. doi: 10.1097/DCR.0000000000000721.
Venous thromboembolism after abdominal surgery occurs in 2% to 3% of patients with Crohn's disease and ulcerative colitis. However, no evidence-based guidelines currently exist to guide postdischarge prophylactic anticoagulation.
We sought to determine the use of postoperative postdischarge venous thromboembolism chemical prophylaxis, 90-day venous thromboembolism rates, and factors associated with 90-day thromboembolic events in IBD patients following abdominal surgery.
This was a retrospective evaluation of an administrative database.
Data were obtained from Optum Labs Data Warehouse, a large administrative database containing claims on privately insured and Medicare Advantage enrollees.
Seven thousand seventy-eight patients undergoing surgery for Crohn's disease or ulcerative colitis were included in the study.
Primary outcomes were rates of postdischarge venous thromboembolism prophylaxis and 90-day rates of postdischarge thromboembolic events. In addition, patient clinical characteristics were identified to determine predictors of postdischarge venous thromboembolism.
Postdischarge chemical prophylaxis was given to only 0.6% of patients in the study. Two hundred thirty-five patients (3.3%) developed a postdischarge thromboembolic complication. Postdischarge thromboembolism was more common in patients with ulcerative colitis than with Crohn's disease (5.8% vs 2.3%; p < 0.001). Increased rates of venous thromboembolism were seen in patients undergoing colectomy or proctectomy with simultaneous stoma creation compared with colectomy or proctectomy alone (5.8% vs 2.1%; p < 0.001). The strongest predictors of thromboembolic complications were stoma creation (adjusted OR, 1.95; 95% CI, 1.34-2.84), J-pouch reconstruction (adjusted OR, 2.66; 95% CI, 1.65-4.29), preoperative prednisone use (adjusted OR, 1.57; 95% CI, 1.19-2.08), and longer length of stay (adjusted OR, 1.89; 95% CI, 1.41-2.52).
This study is limited by its retrospective design.
The use of postdischarge venous thromboembolism prophylaxis in this patient sample was infrequent. Development of evidence-based guidelines, particularly for high-risk patients, should be considered to improve the outcomes of IBD patients undergoing abdominal surgery.
腹部手术后静脉血栓栓塞在2%至3%的克罗恩病和溃疡性结肠炎患者中发生。然而,目前尚无循证指南来指导出院后预防性抗凝治疗。
我们试图确定腹部手术后炎症性肠病(IBD)患者出院后静脉血栓栓塞化学预防的使用情况、90天静脉血栓栓塞发生率以及与90天血栓栓塞事件相关的因素。
这是一项对管理数据库的回顾性评估。
数据取自Optum Labs数据仓库,这是一个大型管理数据库,包含针对私人保险和医疗保险优势参保者的理赔信息。
7078例接受克罗恩病或溃疡性结肠炎手术的患者纳入本研究。
主要结局为出院后静脉血栓栓塞预防率和出院后90天血栓栓塞事件发生率。此外,确定患者临床特征以确定出院后静脉血栓栓塞的预测因素。
本研究中仅0.6%的患者接受了出院后化学预防。235例患者(3.3%)发生了出院后血栓栓塞并发症。出院后血栓栓塞在溃疡性结肠炎患者中比在克罗恩病患者中更常见(5.8%对2.3%;p<0.001)。与单纯结肠切除术或直肠切除术相比,同时行造口术的结肠切除术或直肠切除术患者的静脉血栓栓塞发生率更高(5.8%对2.1%;p<0.001)。血栓栓塞并发症的最强预测因素是造口术(校正比值比[OR],1.95;95%置信区间[CI],1.34 - 2.84)、J形储袋重建术(校正OR,2.66;95%CI,1.65 - 4.29)、术前使用泼尼松(校正OR,1.57;95%CI,1.19 - 2.08)以及住院时间延长(校正OR,1.89;95%CI,1.41 - 2.52)。
本研究受其回顾性设计限制。
在该患者样本中,出院后静脉血栓栓塞预防的使用并不常见。应考虑制定循证指南,尤其是针对高危患者,以改善接受腹部手术的IBD患者的结局。